Low-Dose Atropine and Other Interventions for Pediatric Myopia: A Systematic Review and Bayesian Network Meta-analysis of Efficacy and Post-treatment Outcomes
4 affiliations
- 1IQVIA
- 2IQVIA SA
- 3Santen Pharmaceuticals
- 4Santen SA
Abstract
Introduction Although the comparative efficacy of interventions for pediatric myopia control has been explored, the trade-off between on-treatment efficacy and post-treatment rebound remains unclear. We evaluated the comparative efficacy and durability of effect of low-dose atropine (LDA, <0.1%) vs other interventions for pediatric myopia using Bayesian network meta-analysis (NMA). Methods Randomized controlled trials (RCTs) investigating the efficacy and safety of interventions for pediatric myopia were identified through a systematic review. Outcomes included change from baseline in spherical equivalent refraction (SER) and axial length (AL) after 1 or 2 years of treatment, and 12 months after treatment cessation. Evidence was synthesized in a hierarchical Bayesian NMA with a dose-response ordering constraint model to improve precision and interpretability for decision-making. Heterogeneity was explored in network meta-regressions (NMR). Results The systematic review identified 117 RCTs evaluating 24 active interventions. Twenty-two RCTs and one study arm were excluded from quantitative synthesis because of missing outcomes or violation of the transitivity assumption. LDA concentrations ≥0.01% significantly slowed myopia progression compared with an inactive control over 2 years in a dose-dependent manner and showed numerically larger, though statistically non-significant, effects compared with optical interventions. Moderate‑to‑high dose atropine and repeated low‑intensity red‑light, alone or combined with orthokeratology, showed greater short‑term efficacy; however, 12 months post‑cessation, these interventions were associated with clinically meaningful rebound exceeding progression in untreated controls. In contrast, LDA was not associated with clinically meaningful rebound. Combining 0.01% atropine with orthokeratology improved efficacy relative to LDA monotherapy over 2 years, but post-treatment rebound data were unavailable. NMRs indicated baseline SER, baseline progression, geography, and race as effect modifiers, albeit with borderline significance. Conclusions These findings describe the comparative efficacy and rebound profiles of treatments for pediatric myopia. Within the current evidence base, atropine concentrations of 0.01% to 0.05% showed sustained on-treatment benefit with minimal post-treatment rebound.
Related
- Predicting atropine treatment response heterogeneity in pediatric myopia using explainable machine learning: an on-treatment longitudinal monitoring framework
- Targeted Medical Interventions for the Prevention and Treatment of Viral Hemorrhagic Fever: A Rapid Systematic Review of Updated Intelligence from the 74th Annual Meeting of the American Society of Tropical Medicine and Hygiene
- Nursing interventions for pediatric functional constipation: a systematic review of evidence and clinical implications
- Effects of VR interventions on pediatric ADHD: a systematic review, meta-analysis and exploratory machine-learning analysis
- Mobile health interventions to improve adherence to oral anticoagulant treatment: A systematic review and critical analysis
BibTeX
@article{jovanovic2026lowdose,
title = {{Low-Dose Atropine and Other Interventions for Pediatric Myopia: A Systematic Review and Bayesian Network Meta-analysis of Efficacy and Post-treatment Outcomes}},
author = {Jelena Jovanović and Maria Zacharioudaki and Marilena Kalatzi and Georgios Papadakis and Nagarjuna Mulkalapalli and Frederic Ernst and Thom de Milliano},
journal = {Ophthalmology and Therapy},
year = {2026},
month = sep,
doi = {10.1007/s40123-026-01478-y},
url = {https://doi.org/10.1007/s40123-026-01478-y},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Low-Dose Atropine and Other Interventions for Pediatric Myopia: A Systematic Review and Bayesian Network Meta-analysis of Efficacy and Post-treatment Outcomes
AU - Jelena Jovanović
AU - Maria Zacharioudaki
AU - Marilena Kalatzi
AU - Georgios Papadakis
AU - Nagarjuna Mulkalapalli
AU - Frederic Ernst
AU - Thom de Milliano
PY - 2026
DA - 2026/09/01
JO - Ophthalmology and Therapy
DO - 10.1007/s40123-026-01478-y
UR - https://doi.org/10.1007/s40123-026-01478-y
AB - Introduction Although the comparative efficacy of interventions for pediatric myopia control has been explored, the trade-off between on-treatment efficacy and post-treatment rebound remains unclear. We evaluated the comparative efficacy and durability of effect of low-dose atropine (LDA, <0.1%) vs other interventions for pediatric myopia using Bayesian network meta-analysis (NMA). Methods Randomized controlled trials (RCTs) investigating the efficacy and safety of interventions for pediatric myopia were identified through a systematic review. Outcomes included change from baseline in spherical equivalent refraction (SER) and axial length (AL) after 1 or 2 years of treatment, and 12 months after treatment cessation. Evidence was synthesized in a hierarchical Bayesian NMA with a dose-response ordering constraint model to improve precision and interpretability for decision-making. Heterogeneity was explored in network meta-regressions (NMR). Results The systematic review identified 117 RCTs evaluating 24 active interventions. Twenty-two RCTs and one study arm were excluded from quantitative synthesis because of missing outcomes or violation of the transitivity assumption. LDA concentrations ≥0.01% significantly slowed myopia progression compared with an inactive control over 2 years in a dose-dependent manner and showed numerically larger, though statistically non-significant, effects compared with optical interventions. Moderate‑to‑high dose atropine and repeated low‑intensity red‑light, alone or combined with orthokeratology, showed greater short‑term efficacy; however, 12 months post‑cessation, these interventions were associated with clinically meaningful rebound exceeding progression in untreated controls. In contrast, LDA was not associated with clinically meaningful rebound. Combining 0.01% atropine with orthokeratology improved efficacy relative to LDA monotherapy over 2 years, but post-treatment rebound data were unavailable. NMRs indicated baseline SER, baseline progression, geography, and race as effect modifiers, albeit with borderline significance. Conclusions These findings describe the comparative efficacy and rebound profiles of treatments for pediatric myopia. Within the current evidence base, atropine concentrations of 0.01% to 0.05% showed sustained on-treatment benefit with minimal post-treatment rebound.
SN - 2193-8245
SN - 2193-6528
ER -